Drug-manufacturing robotics startup Multiply Labs raises $75M Series B, total funding tops $100M
ycombinator · x · 2026-10-07
Multiply Labs (YC S16), a San Francisco robotics startup building robots to manufacture complex drugs like gene therapies and mRNA treatments, has raised a $75M Series B led by NantWorks (Patrick Soon-Shiong's holding company), with AstraZeneca, Lux Capital and Founders Fund participating, bringing total funding above $100M.
While AI speeds up drug discovery, manufacturing remains largely manual—slow, contamination-prone, and costing over $1 million per dose for some gene therapies. Multiply's robots now run production inside facilities at customers AstraZeneca and Legend Biotech.
More from Venture
- Everyone's raising from mega funds, yet everyone inside those funds wants out — dauber · 2026-10-07
- Stripe Co-Founder: AI Agents Will Rewire Internet Commerce as Stripe Hits $1.9T, Up 34% — jeff_weinstein · 2026-10-07
- SEO practitioner: backlinks and on-page content are the only two real competitive levers — gaganghotra_ · 2026-10-07
- Indie product ferryman crosses $2,600 MRR — KevinNaughtonJr · 2026-10-07
- AI neocloud Lambda raising up to $4B at $14.5B pre-money ahead of IPO — gharik · 2026-10-07
- LLM-run stock portfolio: 223 picks, MiniMax M3 trading, +5.33% in a month — demian_ai · 2026-10-07